Clinical Trial Update: Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of selumetinib in biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma, has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extrahepatic Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Liver and Intrahepatic Biliary Tract Cancer, Recurrent Extrahepatic Bile Duct Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-04-22